A study to evaluate the safety, tolerability, and efficacy of brodalumab in subjects with rheumatoid arthritis and an inadequate response to methotrexate

• Published in: Journal of rheumatology Vol. 42; no. 6; p. 912
• Main Authors: Pavelka, Karel, Chon, Yun, Newmark, Richard, Lin, Shao-Lee, Baumgartner, Scott, Erondu, Ngozi
• Format: Journal Article
• Language: English
• Published: Canada 01.06.2015
• Subjects: Aged; Antibodies, Monoclonal - administration & dosage; Antibodies, Monoclonal - adverse effects; Antibodies, Monoclonal, Humanized - administration & dosage; Antibodies, Monoclonal, Humanized - adverse effects; Arthritis, Rheumatoid - diagnosis; Arthritis, Rheumatoid - drug therapy; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Injections, Subcutaneous; Male; Maximum Tolerated Dose; Methotrexate - therapeutic use; Middle Aged; Multivariate Analysis; Pain Measurement; Prospective Studies; Retreatment - methods; Risk Assessment; Severity of Illness Index; Treatment Failure; Treatment Outcome; INTERLEUKIN 17; BRODALUMAB; RHEUMATOID ARTHRITIS; RANDOMIZED CONTROLLED TRIAL; PHASE 2

To evaluate the efficacy and safety of brodalumab, a human monoclonal antibody inhibitor of the interleukin 17 receptor, in subjects with rheumatoid arthritis (RA). Patients (n = 252) with inadequate response to methotrexate (MTX) were randomized to receive subcutaneous injections of brodalumab (70...